Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
128M
-
Number of holders
-
71
-
Total 13F shares, excl. options
-
47.6M
-
Shares change
-
+12.5M
-
Total reported value, excl. options
-
$513M
-
Value change
-
+$121M
-
Number of buys
-
59
-
Number of sells
-
-16
-
Price
-
$10.78
Significant Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q1 2022
78 filings reported holding CTKB - Cytek Biosciences, Inc. - Common Stock - $0.001 par value as of Q1 2022.
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) has 71 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47.6M shares
of 128M outstanding shares and own 37.2% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (13.4M shares), HHLR ADVISORS, LTD. (8.76M shares), VANGUARD GROUP INC (6.35M shares), BlackRock Inc. (6.09M shares), Miura Global Management, LLC (2.26M shares), STATE STREET CORP (1.32M shares), GEODE CAPITAL MANAGEMENT, LLC (921K shares), D. E. Shaw & Co., Inc. (734K shares), NORTHERN TRUST CORP (707K shares), and GOLDMAN SACHS GROUP INC (649K shares).
This table shows the top 71 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.